DIRS.INFO The most relevant business & tech news

☆ AstraZeneca tops first-quarter revenue and profit expectations
▼ + stars: | 2024-04-25 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca tops first-quarter revenue and profit expectationsAstraZeneca CEO Pascal Soriot outlines how the pharma giant's first-quarter results were boosted by demand for its rare blood disorder and oncology drugs.

Persons: Pascal Soriot Organizations: AstraZeneca, pharma

☆ AstraZeneca CEO: Objective is to replace chemotherapy
▼ + stars: | 2023-10-24 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca CEO: Objective is to replace chemotherapyPascal Soriot, CEO of AstraZeneca, discusses the progress the company is making with cancer drugs.

Persons: Pascal Soriot Organizations: AstraZeneca

☆ Jefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunities
▼ + stars: | 2023-09-25 | by ( Pia Singh | ) www.cnbc.com time to read: +2 min

AstraZeneca's tozorakimab drug for chronic obstructive pulmonary disease also seems underappreciated, with a potential to reach $4.5 billion in peak sales, according to Jefferies. The firm also suggests up to $3.5 billion in sales for AstraZeneca's eplontersen , a drug aimed at treating hereditary transthyretin-mediated amyloid polyneuropathy. The pharmaceutical giant is also poised to be the frontrunner in breast cancer treatments. Another one of AstraZeneca's breast cancer therapies, also being developed with Daiichi Sankyo, came out with positive news Friday. Its experimental precision drug datopotamab deruxtecan demonstrated an improvement in slowing the progression of a common type of breast cancer in a late-stage trial.

Persons: Peter Welford, Welford, AstraZeneca's, Jefferies, AstraZeneca's eplontersen, transthyretin, deruxtecan, Pascal Soriot's, — CNBC's Michael Bloom Organizations: AstraZeneca, Jefferies, AstraZeneca's, Japan's, pharma Locations: Japan's Daiichi

☆ AstraZeneca succession sickness demands urgent fix
▼ + stars: | 2023-09-15 | by ( Aimee Donnellan | ) www.reuters.com time to read: +3 min

LONDON, Sept 15 (Reuters Breakingviews) - Can a CEO be worth $9 billion? That’s the question posed by the 4% fall in AstraZeneca’s (AZN.L) shares following an article stating boss Pascal Soriot may soon resign. The company has played down the report, and its stock has recovered, but the episode highlights its uncertain position were 64-year-old Soriot to leave. Without a clear succession plan, investors should prepare for further swings. Small wonder investors and analysts wonder whether AstraZeneca will be able to find a successor capable of replicating his success.

Persons: Pascal Soriot, AstraZeneca’s, Ivan Menezes, Debra Crew, Soriot, Susan Galbraith, David Fredrickson, Luke Miels, Soriot’s, Neil Unmack, Streisand Neto Organizations: Reuters, Pfizer, pharma, Novartis, Sanofi, GSK, AstraZeneca, Diageo, Thomson Locations: AstraZeneca’s, Swedish

☆ AstraZeneca seeks to calm CEO speculation after shares drop
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. The company initially declined to comment on the Mail on Sunday report, but later issued a statement saying: "We do not comment on market rumours. AstraZeneca shares closed down 3.2% after earlier touching their lowest since July 19. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July. Reporting by Maggie Fick and Samuel Indyk; Editing by Tomasz Janowski and Mark PotterOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Pascal Soriot, Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Tomasz Janowski, Mark Potter Organizations: AstraZeneca, New York Stock Exchange, REUTERS, Reuters, Times, Thomson Locations: British

☆ AstraZeneca shares fall 3.6% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: 1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) declined as much as 3.6% on Monday, falling to their lowest since July 19. Reuters could not independently verify the information. AstraZeneca declined to comment on the report. Reporting by Samuel Indyk and Maggie Fick; Editing by Amanda CooperOur Standards: The Thomson Reuters Trust Principles.

Persons: Brendan McDermid, Pascal Soriot, Samuel Indyk, Maggie Fick, Amanda Cooper Organizations: AstraZeneca, New York Stock Exchange, REUTERS, Traders, Reuters, Thomson Locations: London

☆ AstraZeneca's Tagrisso-chemo combo results raise bar for J&J cancer drug-analysts
▼ + stars: | 2023-09-11 | by ( Maggie Fick | ) www.reuters.com time to read: +2 min

LONDON, Sept 11 (Reuters) - Data released on Monday by AstraZeneca (AZN.L) from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson's (JNJ.N) rival treatment, analysts said. A brief summary from the Phase 3 trial, called FLAURA2, was released in May, and the detailed data was presented on Monday in Singapore at the World Conference on Lung Cancer. The FLAURA2 trial showed that when adding chemotherapy to Tagrisso, the risk of disease progression or death is reduced by 38% when compared to Tagrisso alone. "With the strong FLAURA-2 data in hand and likely included in treatment guidelines soon, the hurdle is now pretty high in our view for MARIPOSA," the UBS note read. Barclays analysts said the FLAURA2 trial data presented on Monday included doctor and patient surveys that showed a strong preference for the convenience of a single therapy compared with combinations.

Persons: Johnson, Pascal Soriot, Michel Demare, Soriot, Maggie Fick, Emelia Sithole Organizations: AstraZeneca, Lung Cancer, Barclays, UBS, Reuters, Thomson Locations: Singapore, British, MARIPOSA

☆ AstraZeneca shares fall 4% to 7-1/2 week low
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange, U.S., April 8, 2019. REUTERS/Brendan McDermid/File Photo Acquire Licensing RightsCompanies AstraZeneca PLC FollowLONDON, Sept 11 (Reuters) - Shares in London-listed drugmaker AstraZeneca (AZN.L) fell more than 4% on Monday, sliding to their lowest since July 19. An AstraZeneca spokesperson declined to comment on the report. Two of the analysts and the shareholder also mentioned that an article published on Monday in Britain's Times newspaper could have affected the shares, though it appeared to contradict the Mail on Sunday report. The Times' article focused on the retirement of Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca, which was announced in July.

Persons: Brendan McDermid, Pascal Soriot, Mene Pangalos, Pangalos, Pascal, Maggie Fick, Samuel Indyk, Amanda Cooper, Tomasz Janowski Organizations: AstraZeneca, New York Stock Exchange, REUTERS, drugmaker's, Reuters, Britain's Times, Times, Thomson Locations: London

☆ Miners boost FTSE 100 on China optimism; Vistry jumps
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +1 min

Signage for the London Stock Exchange Group is seen outside of offices in Canary Wharf in London, Britain, August 3, 2023. REUTERS/Toby Melville/File Photo Acquire Licensing RightsSummaryCompanies FTSE 100 up 0.6%, FTSE 250 adds 0.4%Sept 11 (Reuters) - The UK's exporter-heavy FTSE 100 index opened higher on Monday boosted by miners after positive China data signalled stability in the world's second-largest economy, while Vistry shares jumped after the homebuilder kept its annual profit outlook. The blue-chip FTSE 100 index (.FTSE) rose 0.6% in early trade, while the mid-cap FTSE 250 index (.FTMC) was up 0.4%. Vistry Group (VTYV.L) jumped 14.4% after the British homebuilder said it would merge its affordable-housing business 'Partnerships' with its Housebuilding operations, while maintaining its annual profit forecast. Reporting by Siddarth S in Bengaluru; Editing by Rashmi AichOur Standards: The Thomson Reuters Trust Principles.

Persons: Toby Melville, British homebuilder, Pascal Soriot, Siddarth, Rashmi Organizations: London Stock Exchange, REUTERS, Vistry, AstraZeneca, The Mail, Barclays, Reuters, Thomson Locations: Canary Wharf, London, Britain, China, British, Bengaluru

☆ Stocks making the biggest moves midday: Tesla, Qualcomm, Meta, Moderna and more
▼ + stars: | 2023-09-11 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

Tesla — Shares of the electric vehicle maker jumped 6% after Morgan Stanley upgraded the stock to overweight from equal weight. Kenvue — Shares of the Band-Aid maker gained 3% after being upgraded by Deutsche Bank to buy from hold on Sunday. The Wall Street firm called Kenvue a high-quality company and believes the stock's slide has created an attractive entry point. Nubank – The U.S.-traded shares of the Brazilian financial firm rose nearly 6% after JPMorgan upgraded Nubank to overweight from neutral. Discovery and Paramount also traded higher on the news, rising 2.2% and 1.9%, respectively,AstraZeneca — The pharmaceutical company's shares lost nearly 3% midday Monday.

Persons: Morgan Stanley, Adam Jones, — Smucker, Alibaba, Daniel Zhang, Zhang, Nubank, Warner, Pascal Soriot, Immatics, — CNBC's Alexander Harring, Samantha Subin, Yun Li, Jesse Pound, Michelle Fox, Tanaya Macheel Organizations: Artificial Intelligence, Hostess Brands, Tenable Holdings, JPMorgan, Deutsche Bank, Alibaba Group, Wall Street, Meta, Qualcomm, Apple, Media, Disney, Charter Communications, Warner Bros . Discovery, Paramount, AstraZeneca, Reuters, Mail, Moderna —, Moderna Locations: Shanghai, U.S, Brazil

SummaryCompanies Q2 sales and earnings beat estimatesReiterates full-year guidanceNo revenue from COVID vaccine in Q2Shares up 3.1% in early tradeCompany is largest drugmaker in ChinaLONDON, July 28 (Reuters) - AstraZeneca (AZN.L) on Friday delivered better-than-expected profits and sales in the second quarter as a strong performance of its blockbuster cancer drugs helped offset the loss of COVID-19 vaccine sales. The Anglo-Swedish drugmaker posted an adjusted profit of $2.15 per share, up 25% and exceeding the $1.98 per share expected in company-compiled consensus estimates. Total revenue in the quarter was $11.4 billion, up 6% and beating company-compiled analyst estimates of $10.97 billion. Excluding COVID medicines, sales in China grew by 7% at constant exchange rates in the quarter, the fourth consecutive quarter of growth on that basis. AstraZeneca is the largest drugmaker in China, which accounted for 13% of last year's revenue.

Persons: Swedish drugmaker, Pascal Soriot, Markus Manns, Alexion, drugmaker, Maggie Fick, Radhika Anilkumar, Nivedita Bhattacharjee, Josephine Mason Organizations: AstraZeneca, UK's, Pfizer, Moderna, U.S, Union Investment, Thomson Locations: China LONDON, Swedish, China, London, Bengaluru

SummaryCompanies Plans to file trial data with FDAComments sooth some investor concernsAbsence of "clinically meaningful" in interim trial data worried investorsLONDON, July 28 (Reuters) - AstraZeneca Chief Executive Pascal Soriot said on Friday the company is "very encouraged" by interim data from a key lung cancer drug trial, but he did not explain why the company had not declared results as "clinically meaningful". The drugmaker's (AZN.L) shares fell by as much as 8% earlier this month after the company released interim data from the late-stage clinical trial called TROPION-Lung01 testing an experimental precision drug called datopotamab deruxtecan. Speaking to media on Friday after the company released better-than-expected quarterly results, Soriot said people would understand when full results are released why the company did not use that description, but he did not comment further. The company said on Friday it will continue with its plan to file data from the trial with the U.S. Food and Drug Administration (FDA), soothing some investor concerns. In a briefing with analysts, Susan Galbraith, executive vice president of oncology R&D, said the FDA response to the data so far had been "encouraging".

Persons: Pascal Soriot, Soriot, Susan Galbraith, Maggie Fick, Josephine Mason, David Evans, Susan Fenton Organizations: LONDON, AstraZeneca, U.S . Food, Drug Administration, FDA, U.S, Thomson

☆ Drugmakers aim to strike down Medicare drug-price negotiations at Supreme Court
▼ + stars: | 2023-06-20 | by ( Spencer Kimball | ) www.cnbc.com time to read: +10 min

And Bristol Myers Squibb is trying protect its blood thinner Eliquis, which brought in $11.8 billion in sales last year, or about 25% of the company's $46 billion total revenue for 2022. Long legal battle aheadMerck, the chamber and Bristol Myers Squibb filed their lawsuits ahead of two key deadlines. Bristol Myers Squibb did not either. If circuit court decisions on the matter contradict one another, the Supreme Court would step in to decide the issue, Bagby said. Bristol Myers Squibb made an identical argument in its complaint.

Persons: Richard A, Gonzalez, Pascal Soriot, Giovanni Caforio, Jennifer Taubert, Johnson, Kenneth C, Frazier, Albert Bourla, Olivier Brandicourt, Win Mcnamee, Drugmaker Merck, Drugmaker, Bristol Myers Squibb, PhRMA, Eli Lilly, Merck, Bristol Myers, Robin Feldman, Nicholas Bagley, Bagley, Gretchen Whitmer, Chris Meekins, Raymond James, Antonin Scalia, Brett Kavanaugh, Neil Gorsuch, Meekins, Long, Xavier Becerra, Randolph Daniel Moss, Barack Obama, Judge Thomas M, Rose, George W, Bush, Kelly Bagby, Bagby, Amgen, Donald Trump, Karine Jean, Pierre, Biden, Jean, we'll, Becerra, Feldman Organizations: Senate, AbbVie Inc, AstraZeneca, Myers Squibb Co, Janssen Pharmaceuticals, Johnson, Merck & Co, Inc, Pfizer, Sanofi, Getty, U.S . Chamber of Commerce, Bristol Myers Squibb, Washington , D.C, Southern, Southern District of, Democratic Party, U.S, Merck, Bristol, Pharmaceutical Research, Manufacturers of America, CNBC, Medicare, University of California College of, Justice Department, Michigan Gov, Bristol Myers, Human Services, Centers, Services, AARP Foundation, HHS, AARP, Specialty Pharmacy, Reuters, Supreme, Appeals, Democratic, U.S . Sixth, Republican, Third, White Locations: America, Washington , DC, Bristol, U.S, Washington ,, Southern District, Southern District of Ohio, New Jersey, Commerce's Dayton , Ohio, San Francisco

BEIJING, May 19 (Reuters) - Global drugmaker AstraZeneca will seek to be a patriotic company in China that "loves the Communist Party", its China president said at an event on Friday. While many local companies have in recent years publicly pledged allegiance to the ruling Chinese Communist Party as President Xi Jinping strengthened the party's role throughout Chinese society and its economy, such messaging is still unusual from foreign companies. "Build a local, transnational company that loves the Communist Party and loves the country," Wang said in his presentation to an audience of a few hundred participants, with the words flashed across the screen behind him. Last year, China accounted for 13% of AstraZeneca's total sales and the company is China's biggest drugmaker. Reporting by Joe Cash in Beijing and Brenda Goh in Shanghai; Editing by Kim CoghillOur Standards: The Thomson Reuters Trust Principles.

☆ GOP law cut Big Pharma tax rates by 40%, Senate report says
▼ + stars: | 2023-05-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

A Republican law has slashed the average tax rates of big pharmaceutical companies by more than 40% since it was enacted in 2017, Senate Finance Committee Democrats said in a report Thursday. That provision allowed U.S.-based pharmaceutical companies to access lower tax rates on their foreign income, the report said. Pharmaceutical companies report 75% of their taxable income overseas, the report said. The report said the average rate fell to 11.6% in 2019 and 2020, which resulted in billions of dollars in tax savings for pharmaceutical companies. Wyden also obtained similar information about other U.S. pharmaceutical companies, including Abbott Laboratories , Amgen , Bristol Myers Squibb and Merck .

☆ AstraZeneca is moving quickly with Covid antibody drug, CEO says
▼ + stars: | 2023-04-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca is moving quickly with Covid antibody drug, CEO saysPascal Soriot, CEO of AstraZeneca, discusses first-quarter earnings and outlines the company's developments in Covid treatments.

LONDON, April 27 (Reuters) - AstraZeneca (AZN.L) on Thursday beat expectations for its first -quarter profit and revenue, helped by sales of its roster of drugs in emerging markets. The London-listed drugmaker, which reports its results in U.S. dollars, reported adjusted profit of $1.92 per share on sales of about $10.9 billion. Excluding sales of its COVID-19 products, sales grew 22% to $3.1 billion in emerging markets on a constant currency basis. AstraZeneca's best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — generated $1.4 billion, $900 million and $651 million of sales, respectively, in the quarter. Cowen analysts expected the three drugs to bring in about $1.45 billion, $735 million and $700 million respectively, in quarterly sales.

The company also predicted a return to growth in China, one of its key markets, after reporting a second consecutive quarter of growth even as prices remain under pressure. Sales of its best-selling cancer drugs — Tagrisso, Imfinzi and Lynparza — came in just below estimates from Cowen analysts. Sales started to pick up in the second half of 2022 and in the fourth quarter grew by 3% at constant currency rates. Of key interest to investors is the experimental cancer drug, datopotamab deruxtecan, being evaluated in a keenly anticipated late-stage trial involving lung cancer patients. Partner Daiichi Sankyo (4568.T) this month said results of that study have been delayed to the second quarter from the first quarter of 2023.

[1/2] The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/Companies AstraZeneca PLC FollowLONDON, Feb 9 (Reuters) - Britain's business climate is deterring biopharma companies from investing in the country, AstraZeneca (AZN.L) chief Pascal Soriot said on Thursday, highlighting his company's decision to shift plans for a new manufacturing plant to Ireland. He highlighted AstraZeneca's recent decision to build a manufacturing facility in Ireland instead of the UK as evidence of Britain becoming less attractive for drugmakers. The decision, made in 2021, was also linked to the UK government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a company spokesperson added. Reporting by Natalie Grover and Maggie Fick Editing by Tomasz Janowski, Barbara Lewis and Susan FentonOur Standards: The Thomson Reuters Trust Principles.

☆ AstraZeneca’s new deal is smarter than it looks
▼ + stars: | 2023-01-09 | by ( ) www.reuters.com time to read: +2 min

LONDON, Jan 9 (Reuters Breakingviews) - On the face of it, Pascal Soriot’s new deal ought to raise his shareholders’ blood pressure. The boss of $221 billion pharma giant AstraZeneca (AZN.L) has agreed to buy CinCor Pharma (CINC.O) for up to $1.8 billion. Yet paying $26 in cash per CinCor share and an extra $10 per share if a key drug is submitted for regulatory approval represents a 206% bump to CinCor’s closing share price on Friday. The pharma industry has a war chest of over half a trillion dollars to splurge on knock-down biotech stocks this year. If the next trial goes better, Astra’s deal may not look so toppy.

☆ The new UK government needs to think long term and fund the NHS and research, AstraZeneca CEO says
▼ + stars: | 2022-11-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailThe new UK government needs to think long term and fund the NHS and research, AstraZeneca CEO saysThe new U.K. government needs to think long term and fund the NHS and research, AstraZeneca CEO Pascal Soriot says

☆ AstraZeneca withdraws U.S. application for COVID vaccine
▼ + stars: | 2022-11-10 | by ( ) www.reuters.com time to read: 1 min

LONDON, Nov 10 (Reuters) - AstraZeneca (AZN.L) is no longer pursuing U.S. approval of its COVID-19 vaccine, Chief Executive Pascal Soriot said in a media call on Thursday. Demand for vaccines in the country is declining and the market is well served by the mRNA shots, he said. Reporting by Natalie Grover in London; Editing by Jan HarveyOur Standards: The Thomson Reuters Trust Principles.

☆ AstraZeneca lifts 2022 earnings outlook as cancer drugs boost results
▼ + stars: | 2022-11-10 | by ( Natalie Grover | ) www.reuters.com time to read: +4 min

AstraZeneca is seen as a bellwether for the pharmaceutical sector in China, which accounted for about 16% of the company's total revenue last year. Sales in China have been hurt by lower drug prices while COVID lockdown measures have kept some patients from being diagnosed and seeking care. Better-than-expected sales of AstraZeneca's cancer medicines, including Tagrisso, Imfinzi and Enhertu, helped the company's quarterly revenue beat, with sales of its broader oncology portfolio rising 24%. But global sales of the company's COVID therapy, Evusheld, have steadily grown, partially offsetting the rapid decline in COVID vaccine sales. Evusheld continues to demonstrate strong efficacy but there are a couple of variants that are resistant to it, Soriot said.

☆ Marea Britanie a aprobat vaccinul anti-Covid produs de AstraZeneca și Universitatea Oxford
▼ + stars: | 2020-12-30 | by ( ) www.jurnal.md time to read: +2 min

Vaccinul conceput de oamenii de știință de la Universitatea din Oxford a fost aprobat pentru utilizare în Marea Britanie, transmite BBC. Acesta marchează un moment de cotitură major și va duce la o extindere masivă a campaniei de imunizare din Marea Britanie. Marea Britanie a comandat 100 de milioane de doze de la producătorul AstraZeneca - suficient pentru a vaccina 50 de milioane de oameni, scrie digi24.ro. El a mai spus că au fost comandate suficiente doze de vaccin pentru a imuniza întreaga populaţie, cu excepţia copiilor. Grupul farmaceutic AstraZeneca susţinea recent că a găsit, după cercetări suplimentare, "formula câştigătoare" pentru vaccinul său împotriva Covid-19 dezvoltat împreună cu Universitatea din Oxford.

Persons: Matt Hancock, Boris Johnson, Pascal Organizations: Universitatea din, BBC, Sunday Times Locations: Universitatea din Oxford, Britanie, britanic, Oxford, AstraZeneca

☆ AstraZeneca a găsit „formula câștigătoare” pentru un vaccin eficient. Serul ar putea fi aprobat în UK în următoarele zile
▼ + stars: | 2020-12-27 | by ( Publika.Md - Aici Sunt Știrile | ) www.publika.md time to read: +3 min

CEO-ul AstraZeneca, Pascal Soriot, a declarat duminică pentru Sunday Times că noile date arată că vaccinul este la fel de eficient precum cel dezvoltat de celelalte companii, Pfizer și Moderna. Soriot și-a mai exprimat încrederea că vaccinul Oxford/AstraZeneca va proteja în fața noilor tulpini ale virusului, scrie libertatea.ro. Împotriva acestei mutaţii, „credem deocamdată că vaccinul ar trebui să-şi menţină eficienţa”, a susţinut Pascal Soriot. Guvernul britanic a anunţat miercuri că a transmis datele complete cu privire la vaccinul Oxford/AstraZeneca organismului naţional de reglementare a vaccinurilor, MHRA. Comisia Europeană a contractat 300 de milioane de doze ale vaccinului, cu opțiunea de a achiziționa încă 100 de milioane.

Persons: Pascal Soriot, . Soriot, Pascal Organizations: Sunday Times, Times, Comisia Locations: Oxford, UE, Regatul Unit şi, Brazilia

Search resuls for: "Pascal Soriot"

25 mentions found